Opugotamig Biosimilar Biparatopic Antibody (Folate Receptor α) for Research

Cat No.: GMP-Bios-INN-1318

Anti-FOLR1 therapeutic antibody (Pre-made Opugotamig biosimilar,Bispecific Mixed mAb and scFv ((G1_L-kappa)_scFvkh-G1(h-CH2-CH3))) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Opugotamig (development code IMGN151) is a bispecific antibody targeting folate receptor alpha (FOLR1). It is developed by ImmunoGen for ovarian cancer, endometrial cancer, and other solid tumors. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1318-1mg 1mg
GMP-Bios-INN-1318-10mg 10mg
GMP-Bios-INN-1318-100mg 100mg
GMP-Bios-INN-1318-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Opugotamig biosimilar, Bispecific Mixed mAb and scFv ((G1_L-kappa)_scFvkh-G1(h-CH2-CH3)), Anti-FOLR1;FOLR1 Antibody: Anti-FOLR1/Folate receptor alpha/FR-alpha/Adult folate-binding protein (FBP) therapeutic antibody
INN Name Opugotamig
Target FOLR1;FOLR1
Format Bispecific Mixed mAb and scFv ((G1_L-kappa)_scFvkh-G1(h-CH2-CH3))
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1;G1
VD LC Kappa;Kappa
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Active
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2024
Year Recommended 2024
Companies ImmunoGen
Conditions Approved na
Conditions Active Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Non-small cell lung cancer
Conditions Discontinued Breast cancer;Cervical cancer
Production na
Development Tech na